Natural killer cell responses in renal transplant patients with cytomegalovirus infection
β Scribed by Heleen Venema; Arie P. Van Den Berg; Coba Van Zanten; Willem J. Van Son; Marijke Van Der Giessen; T. Hauw
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 462 KB
- Volume
- 42
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
β¦ Synopsis
Natural killer (NK) cell function in relation t o immunophenotypical signs of NK activation was studied prospectively in 15 renal transplant patients with cytomegalovirus (CMV) infection. NK activity (expressed as the percentage of K562 ly- sis) before onset of CMV infection reached a median of 6% (range 2-18%), comparable to values observed in noninfected controls [7% (range 7-21%). P < .I]. During CMV infection, NK activity rose to a maximum of 25% (6-6O%) (P < .001 vs. controls). Maximal values exceeded the upper level of controls in nine of 15 patients. NK activity was correlated to the number of CD56'HLADRf cells in the peripheral blood (r = .57, P < .001). These data suggest that NK cells play a role in the recovery from CMV infection in a substantial number of patients and that immunophenotypical analysis of NK activation provides a surrogate marker of NK cell function.
π SIMILAR VOLUMES
Peripheral blood lymphocytes (PBL) from two human cytomegalovirus (CMV)-seronegative donors and eight CMV-seropositive donors were cultured for 3 days with or without the biological response modifier OK-432 and examined for lysis of K562 cells and CMV-infected MRC-5 cells. OK-432-stimulated PBL exhi
## Abstract The early activation of Tβ and Bβcell responses to cytomegalovirus was studied in immunosuppressed patients. Primary lymphocyte stimulation to cytomegalovirus (CMV) antigen, a measure of Tβhelper activity, and antiβCMV IgG subclass responses were analyzed. Ten patients suffering from pr
## Abstract Metastatic renal cell carcinomas (MRCC) are considered as immunogeneic tumors on the basis of the clinical responses observed in patients treated by ILβ2. However, renal cell carcinoma patients are also characterized by alterations of the immune response that may compromise the immunoth